13F Holdings
中文EN

RADX Radiopharm Theranostics Ltd IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1949257 · Fiscal year ends 06/30

Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY1,114.3%
TTM net income YoY20.0%
TTM EPS YoY85.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin1.1%
Operating margin-1,050.6%
Net margin-1,055.3%
FCF margin—
EBITDA margin-979.2%

Returns

ROE-105.2%
ROA-48.4%
ROIC (approx.)-239.1%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets50.4%
Debt / equity0.00x
Current ratio2.67x
Interest coverage-584.59x

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY2025*2025-06-30FY2024*2024-06-30FY2023*2023-06-30
Income statement
Revenue$3.63M$299,228$292,359
Cost of revenue$3.59M——
Gross profit$39,276$299,228$292,359
R&D expense$27.52M$23.09M$22.63M
SG&A expense$14.64M$13.04M$12.23M
Operating income-$38.17M-$47.21M-$34.49M
Interest expense$65,300$642,888$86,091
Pretax income-$38.24M-$47.85M-$34.57M
Income tax$103,292$96,364$38,005
Net income-$38.34M-$47.95M-$34.61M
EBITDA-$35.58M-$44.08M-$31.19M
EPS (basic)-1.76-12.41-11.32
EPS (diluted)-1.76-12.41-11.32
Weighted avg. shares (diluted)2.08B386.46M305.83M
Balance sheet
Cash & equivalents$29.12M$18.58M$11.70M
Receivables$10.40M$987,413$4.47M
Current assets$39.85M$22.85M—
PP&E, netmay include right-of-use assets (IFRS)$53,466$60,797—
Intangibles$46.57M$49.09M$58.54M
Total assets$86.48M$72.04M—
Current liabilities$14.93M$17.58M—
Total liabilities$43.61M$44.68M—
Shareholders' equity$44.79M$28.12M$45.58M
Cash flow statement
Operating cash flow-$36.65M-$22.98M-$23.20M
Capital expenditure——$45,306
Free cash flow——-$23.25M
Investing cash flow$1.77M-$320,000-$1.53M
Financing cash flow$45.43M$30.20M$9.22M
Depreciation & amortization$2.60M$3.13M$3.30M
Stock-based compensation$1.90M$2.64M$3.04M

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.